Evidence map›Paper›PMID 30006376›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2018

Correction: Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment.

Zilin Nie, Fatma Aboulnasr, Sekar Natesampillai, Stephen P Burke, Ashton Krogman, Gary D Bren, Thomas D Y Chung, Jeff R Anderson, Michele K Smart, David J Katzmann and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. The TRAIL: TRAILshort Axis in HIV Immunopathology.Critical reviews in immunology · 2018
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Zilin Nie
Fatma Aboulnasr
Sekar Natesampillai
Stephen P Burke
Ashton Krogman
Gary D Bren
Thomas D Y Chung
Jeff R Anderson
Michele K Smart
David J Katzmann
Govindarajan Rajagopalan
Nathan W Cummins
Andrew D Badley

Funding

Prime shock and kill for HIV erradicationR01AI110173 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2014 to 2024
$6.9M
Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistence.R01AI120698 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2015 to 2019
$2.5M
Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistenceR56AI120698 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2021 to 2021
$607k
NIAID NIH HHS R01 AI120698NIAID NIH HHS R56 AI120698
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID30006376
PMCPMC8592020

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.